Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial Authors: Nina Magnolo, Jennifer Soung, John Frew, Antonio Costanzo, Hiram Ruiz-Santiago, Kilian Eyerich, Mar Llamas-Velasco, Michael Bukhalo, Raja K Sivamani, Angela Moore, Tianshuang Wu, Jiaheng Xie, Manish Patel, Doug Ashley, Blair Kaplan, Vassilis Stakias, Ramon Espaillat, Richard B Warren Published: 2026 ABSTRACT AbstractIntroductionRisankizumab (RZB) and deucravacitinib (DEU) are both approved for the treatment of moderate-to-severe psoriasis. Physicians value head-to-head comparisons between available therapies to make evidence-based treatment decisions. This study evaluates the safety and efficacy of RZB compared with DEU for the treatment of patients with moderate psoriasis who have not previously received biologic treatment.MethodsPatients with moderate psoriasis, eligible for systemic treatment and without prior biologic exposure, were enrolled in a 1:2 ratio to RZB or DEU, respectively. The 52-week treatment was divided into two periods: period A (baseline to week 16) and period B (weeks 16–52). Results from period A are presented here. In period A, patients either received a single subcutaneous injection of RZB 150 mg on day 1 and week 4 or oral DEU 6 mg daily. The coprimary endpoints in period A were achievement of ≥ 90% improvement in Psoriasis Area and Severity Index (PASI 90) and achievement of sPGA 0 or 1 (sPGA 0/1) with at least a two-grade improvement from baseline. Ranked secondary endpoints for period A included the achievement of PASI 100 and sPGA 0 with at least a two-grade improvement from baseline at week 16. Additional endpoints were also assessed. Safety was based on assessment of treatment-emergent adverse events (TEAEs).ResultsA significantly higher proportion of patients treated with RZB achieved PASI 90 (57.3% versus 22.9%), sPGA 0/1 (80.2% versus 39.7%), PASI 100 (27.5% versus 6.5%), and sPGA 0 (27.5% versus 6.9%) compared with patients treated with DEU at week 16 (P < 0.0001). The proportion of patients with TEAEs was 33.6% (RZB) and 42.9% (DEU). Safety was consistent with the known profiles of RZB and DEU.ConclusionsIn this 16-week analysis, treatment with RZB demonstrated superior efficacy compared with DEU in adults with moderate psoriasis. No new or unexpected safety signals were identified.Clinical Trials.ClinicalTrials.gov identifier: NCT06333860.Supplementary InformationThe online version contains supplementary material available at 10.1007/s13555-026-01779-x.Keywords: Moderate psoriasis, Risankizumab, Systemic therapy, Biologics Key Summary Points Why carry out this study?RZB, a biologic, and DEU, a nonbiologic systemic, are both approved for the treatment of moderate-to-severe psoriasis.Head-to-head comparisons are needed to optimize the selection of first-line systemic therapy in patients with moderate psoriasis who have failed initial therapies.This study compares the safety and efficacy of RZB versus DEU in the treatment of patients with moderate psoriasis who have not received prior biologic treatment.What was learned from the study?Significantly higher proportions of patients treated with RZB achieved the coprimary endpoints, PASI 90 and sPGA 0/1, and ranked secondary endpoints, PASI 100 and sPGA 0 (all at week 16), compared with patients treated with DEU. Additionally, more patients treated with RZB achieved Dermatology Life Quality Index of 0/1 (DLQI 0/1) and had higher Treatment Satisfaction Questionnaire for Medication (TSQM) scores compared with those treated with DEU in this 16-week analysis.These 16-week results provide evidence that RZB delivers superior achievement of modern treatment goals like PASI 90 and PASI 100, and health-related quality of life endpoints compared with DEU without new safety signals in biologic-naïve adults with moderate plaque psoriasis. Introduction Psoriasis is a chronic systemic inflammatory skin disease associated with comorbidities such as cardiovascular disease, malignancies, and depression [1]. Psoriasis also negatively impacts patients’ quality of life [2, 3]. In the absence of a cure for psoriasis, currently available therapies provide symptomatic relief. Treatment options for psoriasis include topicals, phototherapy, and systemic therapies, which include biologics and nonbiologics [4–6]. According to the International Psoriasis Council (IPC), patients who have disease involving a body surface area (BSA) > 10%, or involving special body areas such as palms, scalp, or genitals, or failure of topical therapy are considered candidates for systemic therapy [7, 8]. Several biologics, which are administered subcutaneously or intravenously, and oral nonbiologic systemic therapies, are currently available for the treatment of moderate-to-severe psoriasis, but head-to-head comparisons are helpful to physicians to make informed clinical decisions about the first line of systemic treatment [9, 10]. Traditional nonbiologic systemic therapies for psoriasis, including methotrexate, cyclosporine, and apremilast (APR), have limited efficacy in moderate-to-severe patient cases [11, 12]. Deucravacitinib (DEU) represents a new class of oral nonbiologic therapy, approved as a highly selective allosteric inhibitor of the tyrosine kinase 2 (TYK2) enzyme, for the treatment of moderate-to-severe psoriasis. DEU has demonstrated superior efficacy compared with placebo and APR, an oral systemic therapy, on the basis of coprimary endpoints of PASI 75 and sPGA 0/1 at week 16 in patients with moderate-to-severe psoriasis [13]. Biologic agents target specific immune pathways and have revolutionized treatment goals, offering high efficacy and favorable safety profiles [4, 14, 15]. RZB, an approved humanized IgG1 monoclonal antibody that selectively inhibits interleukin-23 (IL-23) by binding to its p19 subunit, has demonstrated greater clinical efficacy and safety in pivotal phase 3 trials for moderate-to-severe plaque psoriasis, as well as in direct comparisons with adalimumab, ustekinumab, and secukinumab [16–18]. RZB has also demonstrated superior efficacy compared with APR in patients with moderate psoriasis on the basis of the achievement of ≥ 90% improvement from baseline in Psoriasis Area and Severity Index (PASI 90) and static Physician’s Global Assessment (sPGA) 0/1 with a two-grade or better improvement from baseline at week 16 [19]. For biologic-naïve patients with more moderate psoriasis who have failed topicals or phototherapy and are considering their first systemic medication, there is limited data to guide therapy selection. This evidence gap is particularly relevant given the availability of newer, higher-potency oral therapies, raising the clinical question of whether to initiate an oral, nonbiologic systemic therapy or a biologic. While both RZB and DEU have demonstrated significant efficacy compared with APR, there are no published head-to-head comparisons between RZB and DEU in the treatment of more moderate psoriasis, leaving practitioners without clear evidence to inform their choice between these two therapies. This phase 4 IMMpactful study was specifically designed to address an important gap by directly comparing the safety and efficacy of RZB and DEU in biologic-naïve patients with more moderate psoriasis who are eligible for systemic therapies. Methods Study Design IMMpactful is a phase 4 multicenter, randomized, open-label, efficacy assessor-blinded, active comparator study examining the safety and efficacy of RZB compared with DEU in patients with moderate psoriasis who are candidates for systemic therapy. IMMpactful is comprised of a screening period of up to 35 days, a 52-week treatment period, and a follow-up phone call for safety (Fig. 1). The treatment period includes period A (baseline to week 16), where patients were centrally randomized at baseline (day 1) in a 1:2 ratio to receive either RZB 150 mg as a single subcutaneous (SC) injection or DEU 6 mg orally once daily (QD). RZB was administered at baseline (day 1) and week 4, and DEU was administered from day 1 until the day prior to the week 16 visit. The final evaluation for efficacy in period A at week 16 is reported here. In the following period B (week 16 to week 52), patients initially randomized to RZB will continue to receive RZB 150 mg as a single SC injection at weeks 16, 28, and 40. Patients initially randomized to DEU will be rerandomized at week 16 in a 1:1 ratio to receive either RZB 150 mg at weeks 16, 20, 32, and 44 or DEU 6 mg orally QD up to week 52. Rerandomization in period B will be stratified by PASI 90 response (responder, nonresponder) at week 16. Rescue RZB 150 mg will be offered to patients who are rerandomized to DEU and have an sPGA > 2 starting at either week 28 or week 40. A list of investigators is provided (Supplementary Table S1). IMMpactful study overview. IMMpactful is divided into two treatment periods: 1) period A, from baseline to week 16, where patients received either RZB 150 mg as a single subcutaneous injection on day 1 and week 4 or DEU 6 mg orally once daily, and 2) period B, week 16 to week 52, where patients initially randomized to RZB in period A continue to receive RZB 150 mg every 12 weeks and patients initially randomized to DEU in period A will be rerandomized at week 16 to RZB 150 mg at weeks 16, 20, 32, and 44 or DEU 6 mg orally QD up to week 52. BSA body surface area, DEU deucravacitinib, PASI Psoriasis Area and Severity Index, PASI 90 ≥ 90% improvement in PASI, PsO psoriasis, QD once daily, RZB Risankizumab, SC subcutaneous, sPGA static Physician Global Assessment. *Stratified by PASI 90 response status. **Rescue with RZB for DEU arm offered to patients with sPGA > 2 at week 28 or week 40 Patients Eligibility criteria for IMMpactful included adult patients (≥ 18 years old) with stable moderate chronic plaque psoriasis, defined as body surface area (BSA) of 10–15%, Psoriasis Area and Severity Index (PASI) ≥ 12, and sPGA of 3 based on a 5-point scale (0 to 4). Patients were candidates for systemic therapy as assessed by the investigator with psoriasis inadequately controlled by topicals, phototherapy, and/or systemic treatments, including but not limited to methotrexate, APR, cyclosporin A, corticosteroids, and/or cyclophosphamide. Patients with any prior exposure to RZB, DEU, or any approved biologics were excluded from this study. This study was conducted following applicable local guidelines and regulations. Approvals were obtained from the local ethics committees of the relevant countries (Supplementary Table S2), and patients provided written informed consent at study initiation. This study was conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Good Clinical Practice Guidelines, the Declaration of Helsinki, as well as applicable local guidelines and regulations. Assessment The coprimary endpoints of period A included the achievement of PASI 90 and sPGA 0/1 with at least a two-grade improvement from baseline at week 16. Ranked secondary endpoints of period A were achievement of PASI 100 at week 16 and achievement of sPGA 0 with at least a two-grade improvement from baseline at week 16. Additional physician-reported endpoints evaluated at week 16 included the change from baseline in PASI, the percent change from baseline in PASI, and the change from baseline in BSA. Patient-reported measures for period A included achievement of Dermatology Life Quality Index of 0 or 1(DLQI 0/1), change from baseline in Psoriasis Symptom Scale (PSS; which measures pain, itching, redness, and burning), percent change from baseline in PSS among patients with baseline score > 0, and mean score on each domain of the Treatment Satisfaction Questionnaire for Medication version 9 (TSQM-9; which measures patient satisfaction across effectiveness, convenience, and global satisfaction). PSS is a 4-item patient-reported questionnaire used in research affiliated with Boehringer Ingelheim and developed in collaboration with researchers from Evidera. Permission to use the scale was requested and approved. Safety and tolerability were assessed by treatment-emergent adverse events (TEAEs), vital sign measurements, physical examinations, and clinical laboratory testing throughout the study. Statistical Analysis All efficacy analyses were conducted on the intention-to-treat populations for period A. The proportions of responders for the coprimary endpoints and ranked secondary endpoints were compared between RZB and DEU using the Cochran–Mantel–Haenszel test, adjusting for the actual values of stratification factors from the initial randomization at baseline. Statistical tests were performed at a two-sided alpha level of 0.05. Nonresponder imputation (NRI), while incorporating multiple imputation to handle any missing data that can be reasonably assumed to be missing at random (NRI-MI) or mixed model repeated measures (MMRM), was used to handle missing data. Results Patient Disposition and Baseline Characteristics Of the 393 patients enrolled in IMMpactful, 131 were randomized to RZB and 262 to DEU (1 patient did not receive study drug) in period A (Fig. 2). Baseline characteristics were mostly balanced across both treatment groups (Table 1). The mean (SD) patient age was 47.3 (14.1) years and 44.8 (13.8) years in the RZB and DEU groups, respectively. The RZB and DEU treatment groups consisted of 38.9% and 37.0% female patients, respectively. The proportion of patients with psoriatic arthritis was 6.9% and 8.4% in the RZB and DEU groups, respectively. At baseline (RZB versus DEU), patients had a mean (SD) BSA of 13.2 (1.6) versus 13.0 (1.6), a mean (SD) PASI of 15.7 (4.2) versus 15.3 (3.3), and a mean (SD) DLQI of 12.0 (7.6) versus 11.3 (6.8). Baseline PASI and BSA were generally lower than those in studies with moderate-to-severe patients, due to the eligibility restriction to sPGA 3 and BSA 10–15%. The mean (SD) duration of psoriasis was 16.1 (14.1) years in the RZB group and 14.1 (11.5) years in the DEU group. IMMpactful patient disposition. DEU, deucravaticinib; RZB, risankizumab Table 1Baseline demographics and clinical characteristics of patients in the IMMpactful studyRZBN = 131DEUN = 262Age, years, mean (SD)47.3 (14.1)44.8 (13.8)Sex, n (%) Female51 (38.9)97 (37.0) Male80 (61.1)165 (63.0)Race,a n (%) Asian8 (6.1)19 (7.3) American Indian or Alaska native05 (1.9) Black or African American6 (4.6)13 (5.0) White117 (89.3)224 (85.8) Missing01BMI, kg/m2, mean (SD)29.9 (7.4)29.5 (7.0)PsA, n (%)9 (6.9)22 (8.4)sPGA 3, n (%)131 (100)261 (99.6)BSA, mean (SD)13.2 (1.6)13.0 (1.6)PASI, mean (SD)15.7 (4.2)15.3 (3.3)DLQI, mean (SD)12.0 (7.6)11.3 (6.8)Duration of plaque psoriasis, years, mean (SD)16.1 (14.1)14.1 (11.5)BMI body mass index, BSA body surface area, DEU deucravacitinib, DLQI Dermatology Life Quality Index, PASI Psoriasis Area and Severity Index, PsA psoriatic arthritis, PsO psoriasis, RZB risankizumab, sPGA 3 static Physician Global Assessment of 3aN = 261 for DEU Baseline demographics and clinical characteristics of patients in the IMMpactful study BMI body mass index, BSA body surface area, DEU deucravacitinib, DLQI Dermatology Life Quality Index, PASI Psoriasis Area and Severity Index, PsA psoriatic arthritis, PsO psoriasis, RZB risankizumab, sPGA 3 static Physician Global Assessment of 3 aN = 261 for DEU Among patients randomized to DEU in period A, four discontinued due to adverse events, seven were lost to follow-up, six withdrew, and one discontinued the study treatment for other reasons (Fig. 3). One patient discontinued RZB in period A due to other reasons (Fig. 3). Coprimary and all ranked secondary endpoints (NRI-MI) of period A in the phase 4 IMMpactful study. Proportion of patients achieving co-primary endpoints, ≥ 90% improvement in Psoriasis Area and Severity Index (PASI 90) at week 16, and static Physician’s Global Assessment of 0 or 1 (sPGA 0/1) with at least a two-grade improvement from baseline at week 16, and proportion of patients achieving all ranked secondary endpoints, PASI 100 at week 16 and sPGA 0 at week 16. ***P < .0001. CI confidence intervals, DEU deucravacitinib, RZB risankizumab. Nonresponder Imputation incorporating Multiple Imputation was used to handle any missing data that can be reasonably assumed to be missing at random Efficacy IMMpactful achieved all primary and ranked secondary endpoints at week 16 (Fig. 3). A significantly higher proportion of patients treated with RZB achieved the coprimary endpoints, PASI 90 (57.3 versus 22.9%, P < 0.0001) and sPGA 0/1 (80.2% versus 39.7%, P < 0.0001) compared with DEU at week 16 (Fig. 3). Likewise, a significantly higher proportion of patients treated with RZB achieved the ranked secondary endpoints, PASI 100 (27.5% versus 6.5%, P < 0.0001) and sPGA 0 (27.5% versus 6.9%, P < 0.0001) compared with DEU at week 16 (Fig. 3). Patients treated with RZB also displayed greater improvements in additional efficacy endpoints. At week 16, patients treated with RZB displayed greater reductions in mean PASI (−13.4 [95% CI −14.3, −12.6] versus −9.3 [95% CI −10.0, −8.7]; nominal P < 0.0001) and percent mean change in PASI (85.7% [95% CI 80.2%, 91.1%] versus 60.4% [95% CI 56.2%, 64.6%]; nominal P < 0.0001) compared with patients treated with DEU (Fig. 4 and Table 2). There was a numerically greater change from baseline in BSA (−10.4 [95% CI −11.5, −9.4] versus −6.2 [95% CI −7.1, −5.4]; nominal P < 0.0001) in patients treated with RZB compared with patients treated with DEU (Table 2). Mean improvement in PASI (MMRI) from baseline in period A. Percent change in PASI at week 16. *** Nominal P < 0.0001. CI confidence intervals, DEU deucravacitinib, PASI Psoriasis Area and Severity Index, RZB risankizumab. MMRM mixed model repeated measures was used to handle missing data Table 2Additional efficacy and patient-reported outcomes in period A of IMMpactfulRZBN = 131DEUN = 262P-valuePASI, nChange in PASI, (95% CI)129−13.4 (−14.3, −12.6)234−9.3 (−10.0, −8.7) < 0.0001BSA, nChange in BSA, (95% CI)130−10.4 (−11.5, −9.4)239−6.2 (−7.1, −5.4) < 0.0001PPASI > 0 at baseline, nChange in PPASI, (95% CI)32−4.6 (−6.5, −2.8)46−2.7 (−4.4, −1.0)0. 09PSS, nChange in PSS, (95% CI)127−5.8 (−6.3, −5.2)230−4.1 (−4.6, −3.7) <0.0001PSS > 0 at baseline, nMean improvement, % (95% CI)126−70.9 (−79.6, −62.3)230−50.5 (−57.2, −43.9) < 0.0001BSA body surface area, CI confidence intervals, DEU deucravacitinib, PASI Psoriasis Area and Severity Index, PPASI Palmoplantar PASI, PSS Psoriasis Symptom Scale, RZB risankizumabNominal P-values reported Additional efficacy and patient-reported outcomes in period A of IMMpactful PASI, n Change in PASI, (95% CI) BSA, n Change in BSA, (95% CI) PPASI > 0 at baseline, n Change in PPASI, (95% CI) PSS, n Change in PSS, (95% CI) PSS > 0 at baseline, n Mean improvement, % (95% CI) BSA body surface area, CI confidence intervals, DEU deucravacitinib, PASI Psoriasis Area and Severity Index, PPASI Palmoplantar PASI, PSS Psoriasis Symptom Scale, RZB risankizumab Nominal P-values reported Patient-Reported Outcomes Patients treated with RZB reported greater benefits in their quality of life and psoriasis symptoms. A greater proportion of patients treated with RZB (64.1% [95% CI 55.9%, 72.3%]) achieved DLQI 0/1 compared with patients treated with DEU (30.5% [95% CI 25.0%, 36.1%]) (Fig. 5A). There was a greater reduction in PSS (−5.8 [95% CI −6.3, −5.2] versus −4.1 [95% CI −4.6, −3.7]; nominal P < 0.0001) and greater percent change in PSS in patients with baseline PSS > 0 (70.9% [95% CI 62.3%, 79.6%] versus 50.5 [95% CI 43.9%, 57.2%]; nominal P < 0.0001) in patients treated with RZB compared with patients treated with DEU (Table 2). Compared with DEU, patients treated with RZB reported higher satisfaction with effectiveness (80.9 versus 62.4, nominal P < 0.0001), satisfaction with convenience (87.1 versus 81.5, nominal P < 0.002), and global satisfaction (87.0 versus 66.5, nominal P < 0.0001) (Fig. 5B). Patient-reported outcomes and treatment satisfaction in period A. A Achievement of DLQI 0/1, B Mean TSQM-9 score for global satisfaction, effectiveness, and convenience. *Nominal P < 0.01; ***nominal P < 0.0001. CI confidence intervals, DEU deucravacitinib, DLQI Dermatology Life Quality Index, MMRM mixed model repeated measures, NRI-MI nonresponder imputation while incorporating multiple imputation, RZB risankizumab, TSQM Treatment Satisfaction Questionnaire for Medication. MMRM and NRI-MI were used to handle missing data Safety In period A, TEAEs were reported in 33.6% of patients treated with RZB compared with 42.9% of patients treated with DEU. Among patients with TEAEs, 6.1% (RZB) versus 15.3% (DEU) had events considered related to the study drug (Table 3). There was one case of serious AE, joint injury, reported in patients treated with RZB, and no serious AE was reported in patients treated with DEU (Table 3). The joint injury, also considered severe, was not related to RZB, and the patient did not discontinue RZB treatment. There was one mild, nonserious AE, episcleritis, leading to RZB discontinuation, and four patients with five AEs leading to discontinuation of DEU (peripheral vascular disease, folliculitis, adverse drug reaction, muscle spasms, and connective tissue disorder). The case of episcleritis was not considered related to RZB treatment. Connective tissue disorder and peripheral vascular disorder were not considered related to DEU treatment. There was one case of nonmelanoma skin cancer (NMSC) reported in patients treated with DEU (Table 3). A single event of hypersensitivity reaction, urticaria, was reported in patients treated with RZB (Table 3). There were seven events of hypersensitivity reactions reported in patients treated with DEU (Table 3). There was one case of a nonserious hepatic event in each treatment group (Table 3). Two cases of herpes zoster were reported in patients treated with DEU (Table 3). Table 3Overview of treatment-emergent adverse event in period ARZBN = 131n (%)DEUN = 261n (%)Adverse events (AEs)44 (33.6)112 (42.9)AEs related to study drug8 (6.1)40 (15.3)Severe AEs1 (0.8)3 (1.1)Serious AEs1 (0.8)0AEs leading to discontinuation of study drug1 (0.8)4 (1.5)Areas of safety interest Injection site reaction2 (1.5)0 Malignancies01 (0.4) Nonmelanoma skin cancer (NMSC)01 (0.4) Malignant tumors excluding NMSC00 Hypersensitivity1 (0.8)7 (2.7) Hepatic events1 (0.8)1 (0.4) Herpes zoster02 (0.8)DEU deucravacitinib, RZB risankizumab Overview of treatment-emergent adverse event in period A DEU deucravacitinib, RZB risankizumab Discussion Treatment options for patients with psoriasis include topical agents, phototherapy, systemics, and biologics. Although effective therapies are available, many patients with psoriasis fail to reach recommended high levels of skin clearance because they receive suboptimal treatment [20–27]. The choice of treatment is affected by variables such as disease severity, areas affected, comorbidities, and safety [28–30]. The increasing number of biologics approved has made stringent skin clearance goals achievable. However, head-to-head comparisons are needed by physicians to make evidence-based treatment decisions [15]. In this phase 4, multicenter, randomized, open-label, efficacy assessor-blinded study, the safety and efficacy of RZB were compared with DEU in a biologic-naïve adults patient population with a moderate BSA involvement that would routinely be managed by oral systemic therapy in clinical practice. The current 16-week achievement of PASI 90, PASI 100, sPGA 0/1, and sPGA 0 results demonstrate that patients treated with two subcutaneous injections of 150 mg RZB achieve rigorous skin clearance among biologic-naïve patients with moderate psoriasis compared with patients treated with a 6 mg DEU daily pill. Traditionally, systemic therapies are introduced at the moderate stage; however, clinical guidelines offer limited data to guide the selection of first-line systemic agents, especially as oral small molecules, such as DEU, become more widely available and may be favored for reasons including perceived convenience or patient preference [20]. In addition to efficacy, the route of administration is a significant factor influencing treatment choice in patients with psoriasis [28, 31–33]. RZB was previously compared with another oral systemic agent, APR [19]. In the study comparing RZB with APR, patients treated with RZB achieved a higher TSQM score for effectiveness, convenience, and global satisfaction at weeks 16 and 52 [19]. This finding aligns with a systematic review evaluating factors influencing patient treatment preferences and satisfaction, which revealed that patients prefer infrequent subcutaneous or intravenous injections over daily oral administration [20, 21]. Furthermore, patients with moderate psoriasis who switched from APR to RZB reported greater satisfaction not only with the effectiveness, but also with the convenience [19]. At week 16 of the current study, patients treated with RZB also reported higher satisfaction with effectiveness, satisfaction with convenience, and global satisfaction compared with patients treated with DEU. A greater proportion of patients treated with RZB also achieved DLQI 0/1 and reported greater improvement in PSS compared with patients treated with DEU. The efficacy results and patient-reported outcomes at this 16-week interim analysis suggest that subcutaneous RZB may represent a superior therapeutic option compared with oral DEU. These findings fill a critical gap, providing evidence for improved alignment between patients’ and physicians’ decision-making for first-line systemic treatment selection. Safety outcomes were consistent with the known profile of RZB. A higher proportion of AEs related to the study drug was reported in patients treated with DEU compared with RZB. One serious adverse event was reported in a patient treated with RZB but not related to medication. There was no serious AE reported in patients treated with DEU. A higher proportion of patients with hypersensitivity reactions were reported with DEU, including rash, dermatitis, and dermatitis acneiform. A single event of nonserious episcleritis, not related to study drug, led to RZB discontinuation. An event of hypersensitivity (urticaria localized to the forearm) was reported in patients treated with RZB. No cases of major adverse cardiac events, serious infection, opportunistic infections excluding tuberculosis and herpes zoster, herpes zoster, malignant tumors excluding NMSC, NMSC, or suicidal ideation and behavior were reported in period A. The safety results for RZB from this study demonstrate consistency with its established safety profile. No new safety concerns were identified in period A of this study. In this current study evaluating the efficacy of RZB, week 16 PASI 90 response rates were similar to the APR head-to-head study in patients with moderate psoriasis but lower than PASI 90 response rates in pivotal studies of RZB in patients with moderate-to-severe psoriasis [18, 19]. Achievement of sPGA 0/1 was generally consistent. One possible explanation for this lower PASI 90 response rate is the known nonlinearity between PASI and disease severity, which in this study was limited to more moderate patients with BSA 10–15%, which may result in lower relative improvements in patient populations with lower PASI scores at baseline [22, 23]. With these results, RZB has now shown superiority in clinical trials to therapies with five different mechanisms of action [16–19]. This study has some limitations. One potential limitation is that this study employs an open-label design rather than a double-blinded design. However, efficacy assessments were conducted in a blinded manner, and this approach has been used in several studies to compare active treatments for psoriasis [16, 24, 25]. There are ongoing efforts to recruit a more ethnically diverse patient population for future studies, which will be more representative of the disease prevalence than that of the current study population. RZB and DEU both act on the interleukin (IL)-23 pathway, but through distinct mechanisms. RZB directly neutralizes IL-23, whereas DEU inhibits intracellular signaling downstream of IL-23 and signaling mediated by several other cytokines [26]. We are currently investigating this pathway, together with additional mechanistic biomarkers in blood and skin, to better understand the molecular basis for the observed differences in efficacy between RZB and DEU. IMMpactful is an ongoing 52-week trial, with results from period A, baseline to 16 weeks, reported here. At week 16, patients either continued RZB or patients who previously received DEU were rerandomized in a 1:1 ratio to receive RZB or DEU until week 52, stratified by PASI 90 response at week 16. The 52-week analysis will provide longer-term results comparing RZB with DEU and the potential to improve treatment outcomes by switching DEU-inadequate responders to RZB in patients with moderate psoriasis. In terms of treatment satisfaction, the 52-week results from patients who switched from DEU in period A to RZB in period B will further inform patients’ preferences between the two medications. Conclusions Results from period A of this phase 4 head-to-head study provide evidence that RZB with two subcutaneous doses at day 1 and week 4 delivers superior rates of skin clearance compared with oral DEU administered daily in biologic-naïve adults with moderate plaque psoriasis at week 16 and demonstrates a safety profile that is consistent with previous studies for RZB. These results support considering RZB as a preferred first-line systemic option in patients with moderate psoriasis due to its high efficacy, skin clearance, and treatment satisfaction early in the treatment decision-making process. Ongoing analyses, including those from subsequent switching to improve treatment outcomes in DEU-inadequate responders at week 16 and long-term periods of this study, will further inform treatment optimization for systemic therapies in moderate psoriasis. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (PDF 265 KB) Acknowledgements This research was funded by AbbVie and supported by the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC) (NIHR203308). Medical Writing/Editorial Assistance Medical writing support was provided by Susan Olalekan, PhD, of AbbVie. Editorial support was provided by Angela T. Hadsell of AbbVie. Medical writing and editorial assistance were funded by AbbVie. Author Contribution Ramon Espaillat, Vassilis Stakias, and Blair Kaplan contributed to the study’s conception and design. Nina Magnolo, Jennifer Soung, John Frew, Antonio Costanzo, Hiram Ruiz-Santiago, Kilian Eyerich, Mar Llamas-Velasco, Michael Bukhalo, Raja K. Sivamani, Angela Moore, and Richard B. Warren managed patients and contributed to data acquisition. Data analysis and interpretation done by Ramon Espaillat, Vassilis Stakias, Blair Kaplan, and Doug Ashley. Nina Magnolo, Jennifer Soung, John Frew, Antonio Costanzo, Hiram Ruiz-Santiago, Kilian Eyerich, Mar Llamas-Velasco, Michael Bukhalo, Raja K. Sivamani, Angela Moore, Tianshuang Wu, Jiaheng Xie, Manish Patel, Doug Ashley, Blair Kaplan, Vassilis Stakias, Ramon Espaillat, and Richard B. Warren all contributed to manuscript writing, critical revision, and approved the final manuscript. Funding AbbVie funded this study (NCT06333860) and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. AbbVie and the authors thank all the trial investigators and patients who participated in this clinical trial. Funding for the journal’s rapid service fee was provided by AbbVie. Data Availability AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (eg, protocols, clinical study reports, synopses, or statistical analysis plans), as long as the trials are not part of an ongoing or planned regulatory submission. These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). Data requests can be submitted at any time after approval in the US and Europe and after acceptance of this manuscript for publication. The data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: https://vivli.org/ourmember/abbvie/ then select “Home.” Declarations Conflict of Interest Nina Magnolo has served as advisor and/or paid speaker for AbbVie, Almirall, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Dr. Wolff, Eli Lilly, Janssen, La Roche-Posay, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB. Jennifer Soung has served as a research investigator, scientific adviser, and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Castle Biosciences, Celgene, Dermavant, Eli Lilly, Incyte, Johnson & Johnson, KoBioLabs, Kyowa Kirin, LEO Pharma, National Psoriasis Foundation (nonprofit), Novartis, Ortho Dermatologics, Pfizer, Regeneron/Sanofi, and UCB. John Frew has conducted advisory work for AbbVie, Actor Pharma, Agilex, Amgen, Apogee, Avalo Therapeutics, Azora, Boehringer-Ingelheim, Bristol-Myers Squibb, Chemocentryx, CSL Behring, Deepcure, Elasmogen, Elgia, Eli Lilly, Fortrea, Frazier, Galderma, Gilde Healthcare, InflaRx, Johnson and Johnson, Kyowa Kirin, LEO Pharma, Medici, Mirador Therapeutics, Moonlake, Nested Therapeutics, Novartis, Regeneron, RxMx, Sanofi, Sonoma Bio, Takeda, UCB, Wiley, Zura Bio; has conducted clinical trials for: AbbVie, Amgen, Avalo Therapeutics, Azora, Boeringer Ingelheim, Bristol Myer Squibb, Chemocentryx, CSL Behring, Eli Lilly, Galderma, InflaRx, Johnson and Johnson, LEO, Moonlake, Novartis, Regeneron, Sanofi, Takeda, UCB; and has received research support from Almirall, Apogee, Avalo Therapeutics, Elasmogen, La Roche Posay, LEO Pharma, Ortho Dermatologics, Sun Pharma, Takeda Pharmaceuticals, UCB. Antonio Costanzo reported receiving grants from AbbVie during the conduct of the study; grants from Galderma and Novartis; and personal fees from Eli Lilly, Janssen, Sanofi, and UCB outside the submitted work. Hiram Ruiz-Santiago has participated in AbbVie-funded studies. He has received honoraria as a speaker and/or advisory board member from AbbVie, Janssen, Elly Lilly, and Bristol Myers Squibb. Killian Eyerich has received honoraria as a speaker and/or advisory board member from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Incyte, Janssen, LEO Pharma, Lilly, Novartis, Sanofi, and UCB. Mar Llamas-Velasco has been an advisory board member, consultant, research support, participated in clinical trials, and/or received honoraria for speaking with the following pharmaceutical companies: AbbVie, Almirall, Amgen, Boehringer, Celgene, Janssen, Leo, Lilly, Kyowa Kirin, Novartis, and UCB. Michael Bukhalo is an investigator on an AbbVie-funded study. Raja K. Sivamani serves as an investigator for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Codex Labs, Dermavant, Eli Lilly, Incyte, Janssen, LEO Pharma, Merck, Moonlake, Novartis, and UCB. He serves as a consultant or speaker for AbbVie, Arbonne, Arcutis, Burt’s Bees, Bristol Myers Squibb, Codex Labs, Eli Lilly, Galderma, Incyte, Leo, Novartis, Nutrafol, Pfizer, Phothera, Regeneron Pharmaceuticals, Sanofi, Sun, Trace Minerals, and UCB. Angela Moore has received honoraria or research funds from AbbVie, Aclaris, Acrotech, Arcutis, Bayer, Bristol Myers Squibb, Cara, Eli Lilly, Galderma, Genentech Roche, Incyte, Janssen, Novartis, Pfizer, Rapt, Regeneron, Roche, and Sanofi.Tianshuang Wu, Jiaheng Xie, Manish Patel, Doug Ashley, Blair Kaplan, Vassilis Stakias, and Ramon Espaillat are employees of AbbVie and may hold stock options. Richard B. Warren has received grants from AbbVie, Almirall, Amgen, Celgene, Janssen, Lilly, LEO Pharma, Novartis, Pfizer, and UCB. He has received personal fees from AbbVie, AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DiCE, Galderma, GSK, Immunocore, Janssen, Lilly, Leo, Meiji Pharma, Nektar Therapeutics, Novartis, Pfizer, RAPT Pharmaceuticals, Sanofi, Sun Pharma, Takeda, UCB & UNION. Richard B. Warren is an Editor-in-Chief of Dermatology and Therapy. Richard B. Warren was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Footnotes Prior Presentation: The results from IMMpactful were presented at the 2025 Fall Clinical Dermatology Conference held from 23–26 October 2025, in Las Vegas, NV, USA: J of Skin. 2025;9 (6) s631. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary file1 (PDF 265 KB) Data Availability Statement AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (eg, protocols, clinical study reports, synopses, or statistical analysis plans), as long as the trials are not part of an ongoing or planned regulatory submission. These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). Data requests can be submitted at any time after approval in the US and Europe and after acceptance of this manuscript for publication. The data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: https://vivli.org/ourmember/abbvie/ then select “Home.”